The United States government has intensified its focus on national security by proposing legislation on limited commercial relations with biotechnology companies in China. This bill, motivated by concerns about the collection of American genetic material, is an effort to protect the interests and security of American citizens.
This initiative arose in response to collaboration between Chinese biotechnology companies and the People’s Liberation Army. According to reports from the US House Select Committee on Strategic Competition, there are fears that US genetic material collected by the Beijing Genomics Institute (BGI) could be used for Chinese military research, including the potential development of biological weapons.
This legislative project not only aims to protect genetic information, but also affects the economic affect scientific competitiveness of the biotechnology sector. The proposal caused a 1.6% decline in the Hang Seng Index, which shows the impact on the stock performance of the Hong Kong stock market. Companies such as WuXi Biologics, pioneers in biotechnology, experienced a significant drop in value, which shows the depth of the impact of these measures on the sector.
This confrontation between the United States and China is not limited to the field of biotechnology, but extends to areas such as artificial intelligence and the aerospace sector. The two countries are engaged in a competition for scientific and technological supremacy with implications that go beyond financial markets and affect the global development of innovation.
As this technological competition develops, an important question arises: Which of these two powers will prevail in global scientific and technological leadership? The course of this competition will not only determine the future of biotechnology, but also the direction of innovation and economic power around the world.